Acorda Therapeutics Inc. is planning regulatory filings in the US by the end of the second quarter, and in the EU by the end of the year, for its inhaled levodopa product CVT-301 for use as a rescue therapy in Parkinson's disease. Shares in Acorda rose as much as 16% in trading on NASDAQ on 9. Feb.
New Phase III results from the 12-week SPAN-PD study show CVT-301 led to statistically significant improvements in Unified Parkinson’s Disease...